Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Gilead Sciences

Tamiflu royalties added $250 million to bottom line.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 1Q

1Q Revenues: $2.1 billion (+36%)

1Q Earnings: $855 million (+45%)

Comments: Atripla HIV treatment sales were $693 million (+36%) while Truvada sales were $658 million (+11%). Sales of pulmonary arterial hypertension drug Letairis were up 40% to $55.5 million. Royalties, contract and other revenues were $298 million, up from $83 million in 1Q09, driven mainly by higher Tamiflu royalties ($246.3 million to $33.2 million) from Roche.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters